SilverCrest Metals
SILV
Cars.com
CARS
Lantheus
LNTH
Collegium Pharmaceutical
COLL
Hutchmed (China)
HCM
US Stock MarketDetailed Quotes
PYPD PolyPid
- 2.8500
- -0.1200-4.04%
Close Dec 26 16:00 ET
19.39MMarket Cap-0.11P/E (TTM)
3.0467High2.8300Low76.52KVolume2.8300Open2.9700Pre Close224.43KTurnover2.13%Turnover RatioLossP/E (Static)6.80MShares9.200052wk High8.99P/B10.26MFloat Cap2.370052wk Low--Dividend TTM3.60MShs Float583.5000Historical High--Div YieldTTM7.30%Amplitude2.3700Historical Low2.9320Avg Price1Lot Size
PolyPid Stock Forum
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits. GREED will make losr and get trapped.
5. Always remember shorts include dark pools.
6. Most importantly, DON’T BLAME ME for your losses. I already give watchlist and stock education. The ball is on you. I give you “watchlist” which means its on w...
GlobeNewswire· 4 mins ago
630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025;
• Upon Potential Positive Phase 3 Data the Company Expects to Submit a New Drug Application ("NDA") for D-PLEX100 under Fast Track and Breakt...
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million
Monday, 23rd December at 7:22 pm
• 630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025;
• Upon Potential Positive Phase 3 Data the Company Expects to Submit a New Drug Application ("NDA") for D-PLEX100 under Fast Track an...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
Wednesday, 11th December at 7:00 am
PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with ImmunoGenesis, Inc. ("ImmunoGenesis"), a Houston-based cli...
PolyPid Announces Research and Development Collaboration With Immunogenesis Leveraging Plex Technology to Enhance Cancer Immunotherapy
Unblinded Interim Analysis to be Conducted Once Approximately 400 PatientsComplete Their 30-Day Follow-up; Top-line Results Expected in the First Quarter of 2025
No comment yet